The pan-Canadian Oncology Drug Review (pCODR) is an evidence-based, cancer drug review process.
The pCODR process is designed to bring consistency and clarity to the assessment of cancer drugs by reviewing clinical evidence, cost-effectiveness, and patient perspectives, and using this information to make recommendations to Canada's provinces and territories (except Quebec) in guiding their drug funding decisions.
Drug Review Updates
Alectinib (Alecensaro) for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (second line)
(Pending Submission as of July 19, 2017)
Fulvestrant (Falsodex) for Locally Advanced or Metastatic Breast Cancer
(Open for Input on Submission until July 31, 2017)
Brentuximab vedotin (Adectris) for Hodgkin’s Lymphoma (post-ASCT) Resubmission
(Pending Submission as of July 13, 2017)
Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia
(Open for Input on Submission until July 24, 2017)
Pembrolizumab (Keytruda) for classical Hodgkin Lymphoma
(Open for Input on Submission until July 21, 2017)
Pembrolizumab (Keytruda) for Metastatic Urothelial Cancer
(Pending Submission as of June 23, 2017)